An Early Phase 1 interventional study of Sarilumab Prefilled Syringe in COVID19, sponsored by ASST Fatebenefratelli Sacco. Withdrawn at 1 site in Italy. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-02-03.
Sponsored by ASST Fatebenefratelli Sacco · Early Phase 1, Interventional, and Treatment
Sarilumab is an anti-interleukin-6 human monoclonal antibody, such as tocilizumab, which is administered subcutaneously every two weeks for the treatment of moderate to severe active rheumatoid arthritis in adult patients. Despite the effectiveness reported for tocilizumab in the recently published experiences, the need to rapidly find alternative therapies to manage the complications of Covid-19 infection remains extremely high. The lack of clinical experience on the usage of sarilumab in such patients prevents the possibility of adopting early access programs for using commercially available sarilumab (prefilled syringe) packs in patients with severe Covid-19 pneumonia. The present study is aimed to generate a rapid, still robustly documented, evidence on the potential clinical efficacy and tolerability of a further IL-6R antagonist in Covid-19 pneumonia.
In February 2020, the emergence of the COVID-19 epidemic in Italy and, especially, in Lombardy, with a potential fatal outcome in a significant proportion of cases, determined the need for adopting new therapeutic approached based on the few data available in literature. Although there are no clinical data available in COVID-19 patients concomitantly treated with Sarilumab subcutaneously (SC) nor intravenously (IV), there is scientific rationale that supports the exploration of sarilumab to treat pulmonary complications related to Covid-195-6. By inhibiting interleukin-6 (IL-6)signaling, sarilumab may potentially interrupt cytokine-mediated pulmonary injury precipitated by infection with SARS-CoV-2 and thereby ameliorate severity and/or reduce mortality among patients presenting with Covid-19 pneumonia when administered in conjunction with antiviral therapy. given the apparent dose/dose pharmacokinetic/ pharmacodynamic (PK/PD) equivalence of 400 mg of tocilizumab to 400 mg of sarilumab, we propose a dose escalation protocol by which the first 5 included patients will be treated with a dosage of 200 mg of sarilumab IV as 1st dose, followed by clinical reassessment after 12 hours and in case of no major adverse events and lack of improvement in respiratory function and / or persistence of fever and persistently high inflammatory markers re-administration of 200 mg intravenous (IV) of sarilumab. If no patients showed unfavorable safety signals, and no clear improvement is detected in >50% of the initially treated five patients after 96 hours since last administration, the dosage will be increase to sarilumab 400 mg IV as first and second dose in the remaining patients.
7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.
Browse COVID-19 studies →ASST Fatebenefratelli Sacco is the lead sponsor of 36 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and \<4 will be requested consent to the study.
Drug: Sarilumab Prefilled Syringe
Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Also known as: Sarilumab
Proportion of patients who show an improvement of the respiratory function
Clinical efficacy of sarilumab in adult patients hospitalized due to severe Covid-19 pneumonia based on the proportion of patients who show an improvement of the respiratory function, described as ≥30% decrease in oxygen requirement compared to baseline (as defined as the ratio of O2 flow through the Venturi mask).
Time frame: 6 weeks
Evaluation of the time to resolution of fever
Evaluation of the time to resolution of fever, defined as body temperature ≤36.6°C axilla, ≤37.8°C rectal or tympanic for at least 48 hours without antipyretics in patients with fever at baseline.
Time frame: 6 weeks
Evaluation of the viral load on blood and sputum for COVID-19
Evaluation of the viral load on blood and sputum for COVID-19
Time frame: Before administration of sarilumab, 48 hours and 96 hours after administration
Evaluation of the plasma concentration of GM-CSF
Evaluation of the plasma concentration of GM-CSF
Time frame: Pre-treatment and 96 and 120 hours post-treatment
Evaluation of the plasma concentration of Il-6
Evaluation of the plasma concentration of Il-6
Time frame: Pre-treatment and 96 and 120 hours post-treatment
Evaluation of the plasma concentration of TNF-α
Evaluation of the plasma concentration of TNF-α
Time frame: Pre-treatment and 96 and 120 hours post-treatment
Evaluation of the rate of progression of White Blood Cell (WBC) fraction
Evaluation of the rate of progression of WBC fraction of immature granulocytes - IG - (absolute count).
Time frame: 96 and 120 hours post-treatment
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ASST Fatebenefratelli Sacco